CRASH-3
2019
Tranexamic Acid in Traumatic Brain Injury
In 12,737 patients with traumatic brain injury, tranexamic acid did not reduce head-injury death overall versus placebo, with benefit in mild–moderate TBI.
Result
Efficacy: Head-injury-related death within 28 daysRR 0.94 (95% CI 0.86-1.02)
Below 1 favours tranexamic acid, above 1 favours placebo.
- Absolute difference
- 1.3 points
The absolute difference is derived from the event rates.
Also reported: Mild–moderate TBI subgroup benefit.
- Subtopic
- Tranexamic acid
- Design
- International RCT
- Relevance
- Supporting: context rather than must-know.
- Also listed in
- Trauma & major haemorrhage
- Source
- CRASH-3 Trial Collaborators. Lancet. 2019;394(10210):1713-1723.doi 10.1016/S0140-6736(19)32233-0
Discussion & critique
Modest overall, but supports early TXA for mild–moderate TBI given the low cost and safety.